Halozyme heads toward Phase III; Roche closes $1.2B Foundation Medicine deal;

@FierceBiotech: ICYMI: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. Story | Follow @FierceBiotech

@JohnCFierce: Alzheimer's startup Alzheon bags $10M and beats a path to Phase III. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: Life sciences entrepreneurs, here is my gift to you: The Biotech Name Generator | Follow @DamianFierce

> Halozyme ($HALO) is back on track for a Phase III trial on its lead pancreatic cancer treatment, detailing its plans to the FDA after the agency lifted a hold on the drug's development. More

> Roche ($RHHBY) wrapped up its deal to take a $1.2 billion stake in Foundation Medicine ($FMI), planning to hand over $150 million over 5 years in a broad R&D collaboration. News

> FierceMedicalDevices takes a look at the world's top med tech companies by 2014 revenue. Report

Medical Device News

@FierceMedDev: FDA approves breath test for stomach disorder, highlights its ease of use over standard of care. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Alere earns FDA clearance for rapid diagnostic of Strep A. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs. Article | Follow @EmilyWFierce

> FDA recalls fall more than 50% in Q1 2015 after reaching record high in 2014. More

> Study: False alarms of breast cancer costing U.S. $4B a year. Story

> Medtronic debuts European study of its atrial fibrillation device. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: UAE drug distributor building a $20M plant in Dubai. Report | Follow @FiercePharma

@EricPFierce: Hospira has now received FDA warning letters for plants on 4 of 7 continents. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire could use boost from adult ADHD med to hit $10B goal. Report | Follow @CarlyHFierce

> Watch out for a two-front hep C price war when Merck's combo hits. Article

> Novo's Tresiba news injects uncertainty in insulin market, particularly for Sanofi. Story

Pharma Marketing News

> Next DTC push for Linzess: Spotlight patients, with big salesforce backup. More

> Pfizer, Merck KGaA suit up for Xalkori marketing wave. Report

> Does pricier mean better to ad consumers? FDA means to find out. Article

> Patient portals open door to lasting relationships with patients, 'Digital Doctor' says. Story

> Pfizer wants Canadians to think EpiPen. What else but a hockey partnership? More

Biotech Research News

> Zurich investigators ID pathway for B cell lymphoma. Item

> Berkeley, Harvard groups highlight new targets for cachexia. Report

> Regulus surges after AstraZeneca snags rights to NASH drug. More

> Whitehead team adapts CRISPR-Cas9 tech to target killer fungal infections. Article

> Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule. Story

Diagnostics News

> Researchers develop paper microchip and smartphone diagnostic for HIV. Item

> OpGen eyes $35M IPO for drug-resistant bacteria tests. Story

> Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D. More

> Alere earns FDA clearance for rapid diagnostic of Strep A. News

> Natera ropes in $55M with eye on cancer Dx. Article

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.